Targeted delivery of antisense oligonucleotides to pancreatic β-cells

Antisense oligonucleotide (ASO) silencing of the expression of disease-associated genes is an attractive novel therapeutic approach, but treatments are limited by the ability to deliver ASOs to cells and tissues. Following systemic administration, ASOs preferentially accumulate in liver and kidney....

Descripción completa

Detalles Bibliográficos
Autores principales: Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Wennberg-Huldt, C., Andersson, E.-M., Valeur, E., Jansson-Löfmark, R., Janzén, D., Sundström, L., Meuller, J., Claesson, J., Andersson, P., Johansson, C., Lee, R. G., Prakash, T. P., Seth, P. P., Monia, B. P., Andersson, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192685/
https://www.ncbi.nlm.nih.gov/pubmed/30345352
http://dx.doi.org/10.1126/sciadv.aat3386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192685/
https://www.ncbi.nlm.nih.gov/pubmed/30345352
http://dx.doi.org/10.1126/sciadv.aat3386

Ejemplares similares